As of today (2026-07-03), the Forward Annual Dividend Yield of Neurocrine Biosciences is 0.00%.
As of today (2026-07-03), the Trailing Annual Dividend Yield of Neurocrine Biosciences is 0.00%.
LTS:0K6R's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Neurocrine Biosciences Forward Dividend Yield % Related Terms
LTS:0K6R vs VTRS, ELAN, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Neurocrine Biosciences (LTS:0K6R) has a Forward Dividend Yield % of 0.00% as of Jul. 03, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Neurocrine Biosciences and its competitors. According to the industry distribution chart, Neurocrine Biosciences ranks #999999 out of 506 companies in the Drug Manufacturers industry.
Is Neurocrine Biosciences' Forward Dividend Yield % too high?
Neurocrine Biosciences' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Neurocrine Biosciences ranks #999999 out of 506 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Forward Dividend Yield % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #999999 out of 506 companies for Forward Dividend Yield %. This places Neurocrine Biosciences in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $185.90, compared to a current price of $172.22 — trading 7.4% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Neurocrine Biosciences' overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Forward Dividend Yield % is 0.00% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $172.22 is trading 7.4% below its estimated GF Value™ of $185.90.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for LTS:0K6R:
Forward Dividend Yield %: 0.00%
GF Value™: $185.90 vs. price of $172.22 (7.4% below fair value)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
97GF Score
Get the complete analysis for LTS:0K6R
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 